AstraZeneca buys Canadian cancer treatment firm for close to £2bn
by August Graham
Mar 19, 2024
1 minute
Drugs giant AstraZeneca has agreed to buy a Canadian company which has a promising new drug designed to treat prostate cancer, in a deal worth as much as 2.4 billion dollars (£1.9 billion).
The London-listed firm said the deal
You’re reading a preview, subscribe to read more.
Start your free 30 days